RxSight, Inc. (NASDAQ:RXST) Director Purchases $504,106.07 in Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley bought 11,111 shares of the stock in a transaction dated Tuesday, November 12th. The shares were bought at an average cost of $45.37 per share, with a total value of $504,106.07. Following the completion of the purchase, the director now directly owns 468,571 shares of the company’s stock, valued at approximately $21,259,066.27. This trade represents a 2.43 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

RxSight Price Performance

NASDAQ:RXST traded down $0.49 during midday trading on Thursday, hitting $44.16. The company’s stock had a trading volume of 1,078,070 shares, compared to its average volume of 489,598. RxSight, Inc. has a fifty-two week low of $26.85 and a fifty-two week high of $66.54. The firm’s 50 day moving average is $50.48 and its 200-day moving average is $53.33. The firm has a market cap of $1.78 billion, a P/E ratio of -53.20 and a beta of 1.19.

Hedge Funds Weigh In On RxSight

Several hedge funds and other institutional investors have recently bought and sold shares of RXST. CWM LLC increased its holdings in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Nisa Investment Advisors LLC boosted its position in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after purchasing an additional 521 shares in the last quarter. Quest Partners LLC purchased a new stake in RxSight in the 2nd quarter worth approximately $41,000. KBC Group NV boosted its position in RxSight by 63.6% in the 3rd quarter. KBC Group NV now owns 1,232 shares of the company’s stock worth $61,000 after purchasing an additional 479 shares in the last quarter. Finally, Amalgamated Bank boosted its position in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analysts Set New Price Targets

RXST has been the subject of a number of research reports. Wells Fargo & Company lowered their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Oppenheimer lowered their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Jefferies Financial Group assumed coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price for the company. Finally, Stifel Nicolaus reduced their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.